Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity.

Despite recent advances in cancer therapy, many malignant tumors still lack effective treatment and the prognosis is very poor. Paclitaxel is a potential anticancer drug, but its use is limited by the facts that paclitaxel is a P-gp substrate and its aqueous solubility is poor. In this study, three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology was evaluated in vitro as a way of enhancing delivery of paclitaxel. Paclitaxel was incorporated both in biotinylated (BP) and non-biotinylated (LP) PEG-PLA nanoparticles by the interfacial deposition method. Small (mean size approximately 110 nm), spherical and slightly negatively charged (-10 mV) BP and LP nanoparticles achieving over 90% paclitaxel incorporation were obtained. The successful biotinylation of nanoparticles was confirmed in a novel streptavidin assay. BP nanoparticles were targeted in vitro to brain tumor (glioma) cells (BT4C) by three-step avidin-biotin technology using transferrin as the targeting ligand. The three-step targeting procedure increased the anti-tumoral activity of paclitaxel when compared to the commercial paclitaxel formulation Taxol and non-targeted BP and LP nanoparticles. These results indicate that the efficacy of paclitaxel against tumor cells can be increased by this three-step targeting method.

[1]  M. Bent.  The role of chemotherapy in brain metastases , 2003 .

[2]  P. Couvreur,et al.  Surface-engineered nanoparticles for multiple ligand coupling. , 2003, Biomaterials.

[3]  C. Dawson,et al.  Biotinylation of membrane proteins accessible via the pulmonary circulation in normal and hyperoxic rats. , 1997, The American journal of physiology.

[4]  H. Sato,et al.  Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol. , 1996, Chemical & pharmaceutical bulletin.

[5]  M. Goris,et al.  Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  Russell J Mumper,et al.  Brain uptake of thiamine-coated nanoparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[7]  M. Taphoorn,et al.  Paclitaxel (Taxol) concentrations in brain tumor tissue. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  W. Oyen,et al.  Pretargeted radioimmunotherapy of cancer: progress step by step. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Matthew Cotten,et al.  Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis , 1994 .

[10]  D. Stewart.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors , 2005, Journal of Neuro-Oncology.

[11]  F. Lang,et al.  Brain Metastases in Patients with Ovarian Carcinoma: Prognostic Factors and Outcome , 2004, Journal of Neuro-Oncology.

[12]  S. Stolnik,et al.  COLLOIDAL STABILITY AND DRUG INCORPORATION ASPECTS OF MICELLAR-LIKE PLA-PEG NANOPARTICLES , 1999 .

[13]  K. Geiger,et al.  Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles , 2004, International journal of cancer.

[14]  R. Mumper,et al.  Paclitaxel nanoparticles for the potential treatment of brain tumors. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[15]  M S Newman,et al.  Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. , 1997, Biochimica et biophysica acta.

[16]  D. D. De Vos,et al.  Targeting of the photocytotoxic compound AlPcS4 to hela cells by transferrin conjugated peg‐liposomes , 2002, International journal of cancer.

[17]  R. Gurny,et al.  Biodegradable nanoparticles for direct or two-step tumor immunotargeting. , 2006, Bioconjugate chemistry.

[18]  H. Yanagie,et al.  Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo , 2001, Pharmaceutical Research.

[19]  W. Pardridge,et al.  Brain-specific expression of an exogenous gene after i.v. administration , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Armin Buschauer,et al.  Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. , 2002, The Journal of clinical investigation.

[21]  D. Reardon,et al.  Molecularly targeted therapy for malignant glioma , 2007, Cancer.

[22]  E. Hall,et al.  Taxol sensitizes human astrocytoma cells to radiation. , 1992, Cancer research.

[23]  S. Simões,et al.  Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[24]  T. Daniels,et al.  Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[25]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  L. Lim,et al.  Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[27]  D. Aggarwal,et al.  Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.

[28]  H. Yanagie,et al.  Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[29]  S. Feng,et al.  Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. , 2004, Biomaterials.

[30]  Hatem Fessi,et al.  Nanocapsule formation by interfacial polymer deposition following solvent displacement , 1989 .

[31]  M. Ferrari,et al.  Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients , 1999, European Journal of Nuclear Medicine.

[32]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.

[33]  P. Kornblith,et al.  Chemotherapy for malignant gliomas. , 1988, Journal of neurosurgery.

[34]  M. Goris,et al.  Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. , 1999, Cancer biotherapy & radiopharmaceuticals.

[35]  D. Ettinger,et al.  Phase I and pharmacodynamic study of taxol in refractory acute leukemias. , 1989, Cancer research.

[36]  J. Beijnen,et al.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[37]  F. D. De Braud,et al.  Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy , 1998, European Journal of Nuclear Medicine.

[38]  K. Shakesheff,et al.  Synthesis and Characterisation of a Degradable Poly(lactic acid)−Poly(ethylene glycol) Copolymer with Biotinylated End Groups , 2001 .

[39]  C. Meares,et al.  Advances in pretargeting biotechnology. , 2001, Biotechnology advances.

[40]  L. Guterman,et al.  A Novel Intravascular Drug Delivery Method Using Endothelial Biotinylation and Avidin-Biotin Binding , 2001, Drug delivery.

[41]  W. Curran,et al.  Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.